Reality Check? Medicaid Costs From Cell, Gene Therapies Projected At (Just) $1Bn-$4Bn By 2030
Executive Summary
Based on the current pipeline of durable therapies, MIT research indicates ‘it’s not a big lift to cover the children and the adults in Medicaid for these products,’ Mark Trusheim says.
You may also be interested in...
Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.
Sickle Cell Gene Therapy May Need New US-Backed Payment Program, Grogan Suggests
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.